Building on a safety culture with transparency by participating in a mentored quality-improvement program for insulin

Julie A Botsford1

  • 1Munson Medical Center, Traverse City, MI. jbotsford@mhc.net.

Abstract

Insights

Munson Medical Center improved insulin pen safety through the ASHP Mentored Quality Improvement Impact Program (MQIIP). Interventions enhanced nurse knowledge and practices, though challenges remain.

Area of Science:

  • Healthcare Quality Improvement
  • Patient Safety
  • Medication Administration

Background:

  • Insulin pen devices are widely used for diabetes management in hospitals.
  • Ensuring safe insulin pen administration is crucial for patient outcomes.
  • Regional medical centers can benefit from structured quality improvement programs.

Purpose of the Study:

  • To describe the experience of a regional medical center participating in the ASHP MQIIP on Insulin Pen Safety.
  • To identify and address safety issues related to insulin pen use in a hospital setting.
  • To evaluate the impact of a quality improvement program on insulin pen safety practices.

Main Methods:

  • Participation in the ASHP Mentored Quality Improvement Impact Program (MQIIP).
  • Baseline assessments to identify nurse knowledge deficits and practice issues.
  • Implementation of new policies, electronic alerts, and targeted education.
  • Collaboration between pharmacy and nursing personnel.

Main Results:

  • Increased nurse knowledge regarding insulin pen safety.
  • Improvements in insulin pen storage, labeling, and injection practices.
  • Enhanced staff awareness of insulin pen safety importance.
  • Persistence of some safety issues requiring further attention.

Conclusions:

  • The ASHP MQIIP provided a structured framework for improving insulin pen safety.
  • Participation facilitated the development of effective communication strategies for staff.
  • The program enhanced the overall safety of insulin pen use at the institution.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
948
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.8K
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
53
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
860